A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

(BE HEARD I)

ID# NCT04242446

​

Recruitment Status: recruiting as of August 2020.

 

Estimated Completion Date: May 2023

​

Sponsors and Collaborators: UCB Biopharma SRL

​

Locations: multiple locations please refer to link above for further information.

​

Contact: UCB Cares 1844599 ext 2273 

​